Radio and PodcastLive Radio & PodcastsLoading page
Opening Radio and Podcast...
Radio and PodcastLive Radio & PodcastsRadio and PodcastLive Radio & PodcastsOpening Radio and Podcast...
Radio and PodcastLive Radio & PodcastsFetching podcast shows and categories...
Radio and PodcastLive Radio & PodcastsFetching podcast episodes...
Radio and PodcastLive Radio & PodcastsFetching episode details...
本期《中国生物技术播客》聚焦康方生物的依沃西单抗将如何改写历史，以及在PD-(L)1/VEGF双抗之间是否即将发生国内头对头三期临床试验。 Could PD-(L)1/VEGF Agents Face Off First In China Phase III Trials?
PD-(L)1/VEGF双抗赛道——中国可否率先改写一线肺癌标准治疗？(Chinese-language podcast) is an episode from Pharma Intelligence Podcasts. 本期《中国生物技术播客》聚焦康方生物的依沃西单抗将如何改写历史，以及在PD-(L)1/VEGF双抗之间是否即将发生国内头对头三期临床试验。 Could PD-(L)1/VEGF Agents Face Off First In China Phase III...
This episode belongs to Pharma Intelligence Podcasts.
Use the player on this page to stream the episode online.
Published Apr 24, 2026, 12:22 long, audio available.
You can listen to PD-(L)1/VEGF双抗赛道——中国可否率先改写一线肺癌标准治疗？(Chinese-language podcast) online on Radio and Podcast. Open the player on this page to stream the available audio.
PD-(L)1/VEGF双抗赛道——中国可否率先改写一线肺癌标准治疗？(Chinese-language podcast) is an episode from Pharma Intelligence Podcasts.
This episode is 12:22 long.
This episode was published on Apr 24, 2026.
May 1, 2026 - 25:06
Apr 30, 2026 - 6:45
Apr 28, 2026 - 7:23
Apr 28, 2026 - 37:42
